Diagnostic Value of a Chimeric TSH Receptor (Mc4)-Based Bioassay for Graves' Disease

Lee, Ji In; Jang, Hye Won; Kim, Sang-Yong; Choi, Joon Young; Kim, Ji Young; Hur, Kyu Yeon; Kim, Jae Hyun; Min, Yong‐Ki; Chung, Jae Hoon; Kim, Sun Wook

doi:10.3904/kjim.2011.26.2.179

Cited by 16 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical sensitivity of the TSI method was absolute (100%), slightly higher than those previously reported for current IMAs and BAs with a similar diagnostic specificity [8,9,[28][29][30][31] (Tables 1 and 3).…”

Section: Discussioncontrasting

confidence: 38%

Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease

Tozzoli

D’Aurizio

Villalta

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

The diagnostic performance of fully automated Immulite TSI assay in GD patients is at least comparable to that of current TRAb immunoassays (IMAs) suggesting the possibility of including such assay in rapid and cost-saving diagnostic and monitoring algorithms. However, our results do not provide full evidence that this assay is specific for S-TRAb only, and future studies comparing Immulite TSI assay to stimulating activity are required.

show abstract

Section: Discussioncontrasting

confidence: 38%

Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease

Tozzoli

D’Aurizio

Villalta

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…We found that TSI were all positive in patients with GD, whereas TSI were all negative in Hashimoto thyroiditis, subacute thyroiditis and healthy controls. The accurate diagnostic value of TSI in GD was also reported in other studies [2,8,[18][19]. Thus, TSI could be used in differential diagnosis of the etiology of thyrotoxicosis.…”

Section: Discussionsupporting

confidence: 74%

The Prognostic Value of Thyroid Stimulating Immunoglobulin in the Management of Graves’ Disease

Chen

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The bioassay of thyroid-stimulating immunoglobulin (TSI) appears to be more sensitive than the commonly used TSH binding inhibition assay (TBII), also known as thyroid receptor antibody assay or TRAb.Methods: An observational study was conducted to evaluate the prognostic value of TSI in clinic. Patients with different etiologies of thyrotoxicosis were enrolled to verified the diagnostic value of TSI.Results: 77 Graves’ disease (GD) patients who were treated with anti-thyroid drug (ATD) were in a continuous follow-up until 1 year after ATD discontinuation. Commercial kits of TSI (Thyretain™) and M22-TBII were used and compared. TSI was all negative in healthy controls, Hashimoto thyroiditis, subacute thyroiditis. TSI value was highest in untreated GD patients (P < 0.001). Under ATD treatment, TSI value decreased gradually. 21 patients had positive TSI at the end of treatment. According to clinical fate of patients with GD after withdrawal ATD, TSI value and positivity in patients with relapse were significantly higher than that reported in patients with remission (P = 0.001, P < 0.001). After adjustment for age, gender, initial TRAb, initial TSI, and TRAb at the end of treatment, the odds ratio (OR) of positive TSI for the risk of relapse was 33.271 (95% confidence interval [CI]: 4.741-233.458, P < 0.001) and OR of quantitative TSI was 1.009 (95% CI: 1.002–1.015, P < 0.001).Conclusions: TSI is a good predictor of relapse in patients with GD subjected to ATD treatment. It might be safer to discontinue ATD when TSI and TRAb were both negative.

show abstract

“…The accurate diagnostic efficacy of TSI in patients with GD was also reported in previous literature. 2,[8][9][10]23,24 Besides, the analysis of TSI level after medication in a follow-up group of patients with GD revealed the correlation between TSI and relapse. Studies have been performed to investigate if TSI may predict relapse or remission after ATD therapy and better sensitivity and specificity have been reported.…”

Section: Discussionmentioning

confidence: 97%

“…The accurate diagnostic efficacy of TSI in patients with GD was also reported in previous literature. 2 , 8 – 10 , 23 , 24 …”

Section: Discussionmentioning

confidence: 99%

The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease

Zhou

et al. 2021

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Background: The bioassay of thyroid-stimulating immunoglobulin was reported to have a similar performance to the commonly used thyroid-stimulating hormone binding inhibition assay, also known as thyroid receptor antibody assay. The normal reference range of thyroid receptor antibody levels indicates the withdrawal of anti-thyroid drugs in the recent clinical guidelines. Methods: A prospective, longitudinal observational study was conducted to evaluate the prognostic value of thyroid-stimulating immunoglobulin in patients with Graves’ disease. Results: A total of 77 patients with Graves’ disease treated with anti-thyroid drugs were in a continuous follow-up until 1 year after anti-thyroid drugs discontinuation. Commercial kits of thyroid-stimulating immunoglobulin and M22-thyroid-stimulating hormone binding inhibition assay were used and compared. Thyroid-stimulating immunoglobulin was all negative in healthy controls, Hashimoto thyroiditis, and subacute thyroiditis. Thyroid-stimulating immunoglobulin value was highest in untreated patients with Graves’ disease ( p < 0.001). Under anti-thyroid drugs treatment, thyroid-stimulating immunoglobulin value decreased gradually. A total of 21 patients had positive thyroid-stimulating immunoglobulin at the end of treatment. According to clinical fate of patients with Graves’ disease after withdrawal of anti-thyroid drugs, thyroid-stimulating immunoglobulin value and positivity in patients with relapse were significantly higher than that reported in patients with remission ( p = 0.001, p < 0.001). After adjustment for age, gender, initial thyroid receptor antibody, initial thyroid-stimulating immunoglobulin, and thyroid receptor antibody at the end of treatment, the odds ratio of positive thyroid-stimulating immunoglobulin for the risk of relapse was 33.271 (95% confidence interval: 4.741–233.458, p < 0.001) and odds ratio of quantitative thyroid-stimulating immunoglobulin was 1.009 (95% confidence interval: 1.002–1.015, p < 0.001). Conclusion: Thyroid-stimulating immunoglobulin is a good predictor of relapse in patients with Graves’ disease treated with anti-thyroid drugs. It might be safer to discontinue anti-thyroid drugs when thyroid-stimulating immunoglobulin and thyroid receptor antibody were both negative.

show abstract

Diagnostic Value of a Chimeric TSH Receptor (Mc4)-Based Bioassay for Graves' Disease

Cited by 16 publications

References 22 publications

Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease

Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves’ disease

The Prognostic Value of Thyroid Stimulating Immunoglobulin in the Management of Graves’ Disease

The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease

Contact Info

Product

Resources

About